The abstract is read at the publisher; the summary is JClub's.
Dynamic ctDNA methylation–guided surveillance in nonmetastatic colorectal cancer after curative resection increases curative-intent metastasis-directed therapy rates (48.1% vs 23.6%).
- Why it matters: Standard CT-based follow-up may detect recurrence too late to enable curative-intent treatment, limiting options for patients after surgery.
- What they did: In the prospective, multicenter randomized phase III FIND trial (NCT05904665), 584 eligible patients were assigned to ctDNA-guided surveillance or standard CT monitoring, with imaging triggered by ctDNA results.
- The result: Recurrence rates were similar (18.0% vs 18.6%, P = .919), but curative-intent treatment was higher (relative risk 2.03, P = .008) with shorter time to clinical recurrence (9.5 vs 13.4 months; lead time 3.9 months; P < .001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.